Company intelligence / Profile preview

Arstasis

Fremont, California, United Statesarstasis.com ↗

Ownership: Private
Development stage: Other

Overview

The company's lead product, the AXERA Access Device (also referred to as "Arstasis One"), was launched in the U.S. in April 2011 after receiving FDA clearance. It introduced a new method for femoral artery access that allowed faster and potentially safer closure compared to traditional techniques. The device penetrated the artery diagonally so tissue overlapped and sealed more quickly than with conventional hollow-bore needles. The company raised significant venture funding but ultimately ceased operations.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Arstasis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arstasis.

Explore the full profile